Open AccessSurvival and complications after neoadjuvant chemotherapy or chemoradiotherapy for esophageal cancer: a meta-analysis
Author(s) -
Jinmin Han,
Zhongtang Wang,
Chengxin Liu
Publication year - 2021
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2021-0021
Subject(s) - medicine , oncology , perioperative , meta analysis , esophageal cancer , neoadjuvant therapy , chemoradiotherapy , chemotherapy , adenocarcinoma , randomized controlled trial , retrospective cohort study , distant metastasis , metastasis , cancer , surgery , breast cancer
Objectives: To identify the effective approach between neoadjuvant chemotherapy (NCT) and chemoradiotherapy (NCRT) by comparing patient survival and complications. Methods: A systematic literature search of articles published between January 1980 and October 2020 was conducted. Data were extracted and analyzed with STATA 12.0. Results: Five randomized trials and 15 retrospective studies, including 4529 patients (NCT: 2035; NCRT: 2494), were enrolled. Compared with NCT, NCRT provided a higher 3-year survival benefit, higher R0 resection and pathological complete response rates and lower local recurrence and distant metastasis rates, but no increase in 5-year survival. Perioperative mortality and cardiovascular complications were more common in patients with adenocarcinoma. Conclusions: Further studies should concentrate on identifying the optimal neoadjuvant approach and suitable beneficiaries.